Artelo Biosciences (ARTL) Competitors $9.58 -0.32 (-3.23%) Closing price 04:00 PM EasternExtended Trading$9.57 -0.01 (-0.09%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. MIRA, TENX, CVKD, CASI, TRIB, MDCX, ENLV, FBLG, RNTX, and RVPHShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include MIRA Pharmaceuticals (MIRA), Tenax Therapeutics (TENX), Cadrenal Therapeutics (CVKD), CASI Pharmaceuticals (CASI), Trinity Biotech (TRIB), Medicus Pharma (MDCX), Enlivex Therapeutics (ENLV), FibroBiologics (FBLG), Rein Therapeutics (RNTX), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors MIRA Pharmaceuticals Tenax Therapeutics Cadrenal Therapeutics CASI Pharmaceuticals Trinity Biotech Medicus Pharma Enlivex Therapeutics FibroBiologics Rein Therapeutics Reviva Pharmaceuticals MIRA Pharmaceuticals (NASDAQ:MIRA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings. Does the media favor MIRA or ARTL? In the previous week, MIRA Pharmaceuticals and MIRA Pharmaceuticals both had 4 articles in the media. MIRA Pharmaceuticals' average media sentiment score of 0.78 beat Artelo Biosciences' score of -0.10 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Artelo Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, MIRA or ARTL? MIRA Pharmaceuticals has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Do analysts recommend MIRA or ARTL? MIRA Pharmaceuticals currently has a consensus target price of $17.00, suggesting a potential upside of 1,097.18%. Artelo Biosciences has a consensus target price of $24.00, suggesting a potential upside of 150.52%. Given MIRA Pharmaceuticals' higher possible upside, analysts plainly believe MIRA Pharmaceuticals is more favorable than Artelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.60 Which has better earnings and valuation, MIRA or ARTL? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.49-2.90Artelo BiosciencesN/AN/A-$9.83M-$19.05-0.50 Is MIRA or ARTL more profitable? MIRA Pharmaceuticals' return on equity of -406.70% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -406.70% -328.44% Artelo Biosciences N/A -497.68%-213.76% Do insiders & institutionals believe in MIRA or ARTL? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 5.8% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryMIRA Pharmaceuticals beats Artelo Biosciences on 8 of the 13 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.74M$3.10B$5.74B$9.59BDividend YieldN/A2.22%4.54%4.09%P/E Ratio-0.5020.5430.3625.02Price / SalesN/A320.02417.70176.88Price / CashN/A42.8237.3459.16Price / Book-4.797.788.956.28Net Income-$9.83M-$54.72M$3.26B$265.47M7 Day Performance-5.43%-0.72%-0.19%-2.02%1 Month Performance-35.92%4.43%3.84%0.34%1 Year Performance21.88%9.17%28.77%20.73% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.837 of 5 stars$9.58-3.2%$24.00+150.5%+31.0%$6.74MN/A-0.505News CoverageEarnings ReportAnalyst ForecastShort Interest ↓MIRAMIRA Pharmaceuticals3.2521 of 5 stars$1.43-3.4%$17.00+1,088.8%-20.2%$27.29MN/A-2.922News CoverageEarnings ReportGap UpTENXTenax Therapeutics1.6847 of 5 stars$5.96-0.8%$17.00+185.2%+41.6%$27.18MN/A-6.489News CoverageEarnings ReportAnalyst RevisionCVKDCadrenal Therapeutics3.1433 of 5 stars$13.05flat$32.00+145.2%N/A$26.75MN/A-1.474Short Interest ↑CASICASI Pharmaceuticals3.5746 of 5 stars$2.19-3.2%$4.00+82.9%-65.5%$26.69M$28.54M-0.85180Upcoming EarningsTRIBTrinity Biotech1.4665 of 5 stars$1.48-5.7%N/A-43.2%$26.53M$61.56M-0.50480News CoverageGap UpMDCXMedicus Pharma2.1016 of 5 stars$1.95-2.3%$23.50+1,102.3%N/A$26.52MN/A-1.46N/ANews CoverageAnalyst RevisionHigh Trading VolumeENLVEnlivex Therapeutics3.3091 of 5 stars$1.13-10.0%$10.00+788.9%-16.7%$26.37MN/A-1.6970News CoverageAnalyst ForecastShort Interest ↓Gap UpHigh Trading VolumeFBLGFibroBiologics2.933 of 5 stars$0.61-1.3%$13.00+2,034.6%-54.0%$25.51MN/A-1.6910News CoverageShort Interest ↑Gap UpRNTXRein TherapeuticsN/A$1.10-2.7%N/AN/A$25.36MN/A-0.419News CoverageEarnings ReportAnalyst DowngradeGap UpRVPHReviva Pharmaceuticals2.8471 of 5 stars$0.53+1.3%$7.17+1,262.5%-33.3%$25.10MN/A-0.805Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst Revision Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives Tenax Therapeutics Alternatives Cadrenal Therapeutics Alternatives CASI Pharmaceuticals Alternatives Trinity Biotech Alternatives Medicus Pharma Alternatives Enlivex Therapeutics Alternatives FibroBiologics Alternatives Rein Therapeutics Alternatives Reviva Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access